p53 mutation and cancer
p53 MUTATIONS IN LEUKEMIA AND LYMPHOMA
Download a recent review
Peller, S. & Rotter, V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 21, 277-284 (2003). -> download
Alterations in the p53 gene are less common in hematological malignancies (10 to 15%) than in solid tumors. Nevertheless, the incidence was found to increase in some cases with disease progression and was associated with a poor prognosis. Analysis of the mutational event leading to p53 gene mutations in leukemia and lymphoma indicates that 50% of the mutations are GC->AT transitions which are predominantly located at the CpG dinucleotide. It suggests that most of the mutations that alter the p53 gene are due to endogenous processes related to the deamination of 5-methylcytosine. In fact, the three hot spot codons 175, 248 and 273 contain such a dinucleotide.